Back to Search
Start Over
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
- Source :
-
BioMed Research International . 4/24/2019, p1-15. 15p. - Publication Year :
- 2019
-
Abstract
- Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANTIGENS
*CANCER
*CANCER chemotherapy
*COLON tumors
*GENE expression
*HEAD tumors
*IMMUNOTHERAPY
*LUNG cancer
*MELANOMA
*MEMBRANE proteins
*METASTASIS
*NECK tumors
*PANCREATIC tumors
*RENAL cell carcinoma
*SURVIVAL
*TUMOR markers
*TUMORS
*URINARY organs
*PATIENT selection
TUMOR prognosis
RECTUM tumors
Subjects
Details
- Language :
- English
- ISSN :
- 23146133
- Database :
- Academic Search Index
- Journal :
- BioMed Research International
- Publication Type :
- Academic Journal
- Accession number :
- 136065164
- Full Text :
- https://doi.org/10.1155/2019/9056417